Untitled
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk | Circulation
IJMS | Free Full-Text | Daily Lifestyle and Cutaneous Malignancies
ZHIMIN WANG | Institut Curie
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial - The Lancet Neurology
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines: Cell Systems
Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection | Science Immunology
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention - ScienceDirect
SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants | mBio
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells | Science
Detecting anti–SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion | Science Advances
Publications | Dhanasekaran Lab | Stanford Medicine
RAD51B in Familial Breast Cancer | PLOS ONE
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV) | eLife
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection | Science
SIOP ABSTRACTS - 2018 - Pediatric Blood & Cancer - Wiley Online Library
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences | eLife
Advances and gaps in SARS-CoV-2 infection models | PLOS Pathogens
A Highly Potent SARS-CoV-2 Blocking Lectin Protein | ACS Infectious Diseases
Absolute quantitation of individual SARS-CoV-2 RNA molecules provides a new paradigm for infection dynamics and variant differences | eLife
JCM | Free Full-Text | Severe COVID-19: Drugs and Clinical Trials
